Global Neuropathic Pain Market Research Report, by Drug Types (anticonvulsants, antidepressant, anaesthesia, steroids and other), by condition (peripheral neuropathy, diabetic neuropathy and other), by End User (retail pharmacies, hospitals and other) – Forecast Till 2023
Neuropathic pain Market is a complex and chronic pain that usually occurs due to tissue damage. During this state nerve fibers damage themselves and this damage to nerves sends incorrect signals to pain centers. Increasing number of diabetic and cancer patients together are the major driving factor for this market’s growth. Beside this increasing approval of novel treatment for neuropathic pain, increasing number of pain management centers and increasing demand for generic drugs has provided a fuel for the growth of this market. On the other hand increasing cost of branded drugs and increasing side effects of the steroid therapy can restrain the growth of this market.
Global neuropathic pain market is expected to grow at the CAGR of 5.5% during forecasted period.
Based on regions global neuropathic pain market is segmented into North America, Europe, Asia Pacific plus Middle East and Africa. North America and Europe has share in more than half of the global neuropathic pain market. Due to the well-developed medical and pharmaceutical sector, government supports research and development. Along with this increasing prevalence of disease which causes neuropathic pain especially diabetic and cancer is the major driving factor for neuropathic pain market in North America and Europe. Asia Pacific has given opportunities for developing neuropathic pain market here due to increasing demand of drugs for neuropathic pain and increasing prevalence of disease like diabetes.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1390 .
Key Players in the global Neuropathic Pain Market
Some of the key players in this market are Pfizer Inc., Depomed Inc., Johnson & Johnson Services Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A, Baxter Healthcare Corporation, and Biogen Idec Inc.
This market is segmented into by drug types (anticonvulsants, antidepressant, anaesthesia, steroids and other), by condition (Peripheral Neuropathy, Diabetic Neuropathy and other) and by end user (retail pharmacies, hospitals and other)
On the basis of application it is segmented into peripheral neuropathy, diabetic neuropathy and others. On the basis of end users the market is segmented into retail pharmacies, hospitals and others.
There are many key players in the global neuropathic pain market. Some of them are Pfizer Inc., Depomed Inc., Johnson & Johnson Services Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A, Baxter Healthcare Corporation and Biogen Idec Inc.
Due to increasing prevalence of neuropathic pain globally many companies are in the race to introduce better oral treatment for neuropathic pain. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize competition in the market.
Pfizer is one of the leading pharmaceutical companies of the world. They have introduced LYRICA (pregabalin) for management of neuropathic pain associated with spinal cord injury which is approved by FDA. Earlier this drug was used for the treatment of neuropathic pain associated with diabetes. They have also introduce PainDETECT which is a simple screening tool developed to detect neuropathic pain (NeP) components in patients suffering from low back pain.
Depomed Inc. a pharmaceutical company focuses on products to treat pain and CNS condition, this company has introduced Lazanda® (fentanyl) nasal spray CII for the management of pain in cancer patients and Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate or acute pain.
Eli Lily and Company has introduced CYMBALTA® (duloxetine HCl) which is FDA approved antidepressant for the treatment of pain caused due to diabetic peripheral neuropathy.
GlaxoSmithKline a UK based pharmaceutical company has submitted results of phase II clinical trial for Horizant™ which manages neuropathic pain associated with post-herpetic neuralgia. They are performing clinical trials for NCT00969059 to be used for the treatment of neuropathic pain patients with peripheral nerve injury.
Biogen Idec Inc. has introduces CNV1014802 (raxatrigine) use for the treatment of neuropathic pain.
Browse complete report at https://www.marketresearchfuture.com/reports/neuropathic-pain-market .
The report of global neuropathic pain market by Market Research Future comprises of extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the market’s segments and regions.
Table of Content
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
More Enquire at https://www.marketresearchfuture.com/enquiry/1390 .
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL NEUROPATHIC PAIN MARKET, BY DRUG TYPE
6. GLOBAL NEUROPATHIC PAIN MARKET, BY DISEASE CAUSE
6.1 PERIPHERAL NEUROPATHY
6.2 DIABETIC NEUROPATHY
7. GLOBAL NEUROPATHIC PAIN MARKET, BY END USER
7.1 RETAIL PHARMACIES
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –